
ANTIMICROBIAL ACTIVITY OF SULFONAMIDES: HISTORICAL DEVELOPMENT, MECHANISMS OF ACTION, RESISTANCE PATTERNS, AND CURRENT APPLICATIONS

Dr. Devendra Kumar

Assistant Professor in Dept. of Chemistry,

Shri Mahendra Pal Shastri Mahavidyalaya Bhawankhera Aligarh

Abstract

Sulfonamides represent one of the earliest classes of antimicrobial agents developed for clinical use and continue to play a significant role in modern antimicrobial therapy. This comprehensive review examines the historical development, mechanisms of action, spectrum of activity, resistance patterns, and current applications of sulfonamides. The discovery of sulfonamides in the 1930s marked a pivotal moment in medical history, providing the first effective treatment against many bacterial infections. This review also explores emerging applications, structure-activity relationships, and the ongoing development of novel sulfonamide derivatives designed to overcome resistance mechanisms and expand therapeutic utility. Despite challenges from antimicrobial resistance, sulfonamides continue to serve as important tools in the antimicrobial armamentarium and as structural templates for drug development beyond antimicrobial applications.

Keywords: Sulfonamides, antimicrobial resistance, dihydropteroate synthase, folate pathway, trimethoprim, structure-activity relationship, bacteriostatic agents

1. Introduction

The discovery and development of sulfonamides in the 1930s heralded the beginning of the modern antimicrobial era, representing the first effective systemic antibacterial agents available to medicine (Lesch, 2007). Initially derived from azo dyes, sulfonamides transformed the treatment of bacterial infections and dramatically reduced mortality from previously deadly conditions such as puerperal sepsis, meningitis, and pneumonia (Aminov, 2010). Their introduction predated penicillin's clinical use and established the framework for rational drug development in antimicrobial therapy.

Sulfonamides belong to a class of synthetic antimicrobial compounds characterized by the presence of the sulfonamide functional group ($-\text{SO}_2\text{NH}_2$). Their core structure consists of a benzene ring with a sulfonamide group at the para position relative to an amine or substituted amine group. This structural backbone has been extensively modified to produce numerous derivatives with varied pharmacokinetic properties and antimicrobial spectra (Maren, 1976).

While the rise of antimicrobial resistance and the development of newer antibiotics have diminished the primacy of sulfonamides, they remain clinically relevant due to their broad spectrum of activity, oral

bioavailability, low cost, and effectiveness in specific applications. The combination of trimethoprim and sulfamethoxazole (co-trimoxazole) represents one of the most widely prescribed antimicrobial combinations globally, highlighting the enduring utility of sulfonamides in contemporary medicine (Huovinen, 2001).

This review aims to provide a comprehensive examination of sulfonamides as antimicrobial agents, tracing their historical development, elucidating their mechanisms of action and resistance, discussing their spectrum of activity against various pathogens, and exploring their current applications in clinical practice. Additionally, we will address recent advances in sulfonamide research, including the development of novel derivatives designed to overcome resistance mechanisms and structural modifications to enhance their antimicrobial efficacy and reduce toxicity.

2. Chemical Structure and Classification

2.1 Basic Structure

Sulfonamides share a common structural feature: the sulfonamide moiety ($-\text{SO}_2\text{NH}_2$) connected to a benzene ring. The general chemical structure consists of a benzene ring substituted at the para position with the sulfonamide group and an amino group or substituted amino group at the ortho position. The basic pharmacophore of antimicrobial sulfonamides is 4-aminobenzenesulfonamide, also known as sulfanilamide, which bears structural similarity to p-aminobenzoic acid (PABA), a substrate in bacterial folate synthesis (Sköld, 2000).

2.2 Structure-Activity Relationships

Several structure-activity relationships have been established for sulfonamides:

1. The free amino group ($-\text{NH}_2$) at the N^4 position is essential for antimicrobial activity, as it is critical for competing with PABA for the active site of dihydropteroate synthase.
2. Substitutions at the N^1 position (sulfonamide nitrogen) affect pharmacokinetic properties, tissue distribution, and potency.
3. Electron-withdrawing groups on the benzene ring enhance antibacterial activity by increasing acidity of the sulfonamide NH proton.
4. Lipophilicity influences tissue penetration and serum protein binding.
5. The sulfonamide group must be directly attached to the benzene ring for optimal antimicrobial activity.

3. Mechanism of Antimicrobial Action

Sulfonamides act as antimetabolites, structurally resembling p-aminobenzoic acid (PABA), an essential precursor in bacterial folate synthesis. By capitalizing on this structural similarity, sulfonamides interfere with a critical metabolic pathway in many bacteria (Bushby and Hitchings, 1968; Woods, 1940).

3.1 Folate Pathway Inhibition

Tetrahydrofolic acid (THF) is an essential cofactor for the synthesis of purines, thymidine, and certain amino acids. While mammalian cells can utilize preformed folate from dietary sources, most bacteria must

synthesize folate de novo from PABA and pteridine precursors. This metabolic difference provides a selective target for antimicrobial action.

The folate synthesis pathway in bacteria involves several enzymes, with dihydropteroate synthase (DHPS) playing a pivotal role by catalyzing the condensation of PABA with dihydropterin pyrophosphate to form dihydropteroic acid. Sulfonamides competitively inhibit DHPS by mimicking PABA's structure, thereby preventing incorporation of the authentic substrate into the growing folate molecule (Achari et al., 1997).

3.2 Synergy with Dihydrofolate Reductase Inhibitors

Dihydrofolate reductase (DHFR) catalyzes the conversion of dihydrofolate to tetrahydrofolate, the step immediately following the reaction catalyzed by DHPS. Inhibitors of DHFR, such as trimethoprim, act synergistically with sulfonamides by creating a sequential blockade in the folate pathway. This synergistic action:

1. Enhances antimicrobial efficacy
2. Broadens the spectrum of activity
3. Reduces the emergence of resistance
4. Permits lower doses of each agent, potentially reducing toxicity

The combination of trimethoprim and sulfamethoxazole (co-trimoxazole) exemplifies this approach, with the agents typically formulated in a 1:5 ratio to achieve optimal synergistic effect while maintaining appropriate serum concentrations (Huovinen, 2001).

3.3 Bacteriostatic versus Bactericidal Activity

Sulfonamides are primarily bacteriostatic agents, inhibiting bacterial growth rather than directly killing bacteria. However, under certain conditions, they may exhibit bactericidal effects:

1. In environments with low PABA concentrations
2. Against highly susceptible organisms
3. At high concentrations
4. When combined with other antimicrobials

The bacteriostatic nature of sulfonamides has implications for their clinical use, particularly in immunocompromised patients where bactericidal activity may be preferable. However, the bacteriostatic action is often sufficient for clinical efficacy when host defense mechanisms are intact (Libecco and Powell, 2004).

5. Pharmacokinetics and Pharmacodynamics

The clinical utility of sulfonamides is significantly influenced by their pharmacokinetic and pharmacodynamic properties, which vary considerably among different compounds in this class.

5.1 Absorption

Most sulfonamides are well absorbed from the gastrointestinal tract after oral administration, with bioavailability typically ranging from 70% to nearly 100%. Factors affecting absorption include:

- **Solubility:** More soluble compounds generally demonstrate better absorption.

- **pKa:** Compounds with lower pKa values (5.0-6.0) tend to be better absorbed than those with higher values.

- **Food:** Absorption may be delayed but not significantly reduced by food.

- **Disease states:** Malabsorption syndromes can reduce bioavailability.

Topical formulations (e.g., silver sulfadiazine for burns) are primarily intended for local action with minimal systemic absorption, although some absorption can occur, especially from extensive denuded areas (van der Vijver et al., 2012).

5.2 Distribution

After absorption, sulfonamides distribute widely throughout body tissues and fluids:

- **Volume of distribution:** Typically, 0.2-0.3 L/kg, indicating distribution primarily in extracellular fluid.
- **Protein binding:** Highly variable (15-95%), affecting free drug concentration and antimicrobial activity. Compounds with higher protein binding generally have longer half-lives.
- **Tissue penetration:** Good penetration into most tissues, including the prostate, synovial fluid, and middle ear fluid.
- **CNS penetration:** Variable penetration into cerebrospinal fluid, though adequate levels for treatment of CNS infections can be achieved with certain compounds (e.g., sulfadiazine).
- **Placental transfer:** Sulfonamides cross the placenta and can reach therapeutic concentrations in fetal circulation.
- **Breast milk penetration:** Sulfonamides are secreted in breast milk, typically at concentrations 50-70% of those in maternal serum.

5.3 Metabolism and Elimination

Sulfonamides undergo various metabolic transformations, primarily in the liver:

- **Acetylation:** The primary metabolic pathway, mediated by N-acetyltransferase. The rate of acetylation is genetically determined, with populations categorized as "fast" or "slow" acetylators.
- **Glucuronidation:** Formation of glucuronide conjugates, particularly with N4-hydroxylated metabolites.
- **Oxidation:** Formation of hydroxylated metabolites via cytochrome P450 enzymes.

Elimination occurs primarily via the kidneys through:

- Glomerular filtration of free (unbound) drug
- Tubular secretion of both parent compound and metabolites
- Limited tubular reabsorption, influenced by urine pH (acidic urine decreases reabsorption) (Mitscher, 2002).

5.4 Pharmacodynamics

The antimicrobial efficacy of sulfonamides is primarily determined by:

- **Time-dependent killing:** The duration for which free drug concentrations exceed the minimum inhibitory concentration (MIC) is the primary determinant of efficacy.
- **Post-antibiotic effect:** Minimal to absent post-antibiotic effect, unlike many other antimicrobial classes.

- **Concentration to MIC ratio:** The ratio of peak concentration to MIC appears less important than time above MIC.
- **Inoculum effect:** Activity may be reduced against high bacterial loads.

For the trimethoprim-sulfamethoxazole combination, the optimal bacteriological effect is achieved when the concentration ratio is approximately 1:20, corresponding to an approximately 1:5 weight ratio in formulations (Bushby and Hitchings, 1968).

6. Mechanisms of Resistance

The widespread use of sulfonamides has inevitably led to the development of resistance among many bacterial species. Understanding these resistance mechanisms is crucial for the appropriate clinical application of these agents and for developing strategies to overcome resistance. The most common mechanism of chromosomal resistance involves mutations in the folP gene encoding dihydropteroate synthase (DHPS). These mutations result in alterations in the enzyme's structure that reduce its affinity for sulfonamides while maintaining affinity for the natural substrate, PABA. Key mutation patterns include:

- Substitutions in amino acids 55-57 in many gram-negative bacteria
- Changes in the conserved loop region (amino acids 187-195) in pneumococci
- Multiple mutations conferring high-level resistance in streptococci

These mutations typically confer cross-resistance to all sulfonamides, though the degree of resistance may vary among different compounds (Sköld, 2000).

7. Clinical Applications

Despite the rise of antimicrobial resistance and the development of newer agents, sulfonamides continue to hold clinical relevance both as monotherapy and in combination therapies. Their broad utility across multiple systems reflects their cost-effectiveness and versatility.

Trimethoprim-sulfamethoxazole (TMP-SMX) remains a valuable first-line treatment for uncomplicated community-acquired UTIs, especially in regions where resistance rates are below 20%. The drug concentrates in the urine at levels 5–10 times higher than in serum, enhancing its efficacy. While its role in complicated UTIs and pyelonephritis is limited due to resistance and alternative options, TMP-SMX remains effective when susceptibility is confirmed (Gupta et al., 2011).

Although resistance has reduced their use in respiratory infections, sulfonamides still serve as alternative therapy in specific scenarios. TMP-SMX can be used in acute exacerbations of chronic bronchitis when first-line drugs are contraindicated and for community-acquired pneumonia in low-resistance areas. It remains the drug of choice for treating *Pneumocystis jirovecii* pneumonia (PJP) and is used in lower doses for prophylaxis in immunocompromised individuals, such as those with HIV/AIDS (Fishman, 2002).

Sulfonamides are occasionally used in gastrointestinal conditions like traveler's diarrhea and shigellosis, though rising resistance has curtailed their effectiveness. Sulfasalazine, a sulfonamide derivative, is used

in inflammatory bowel disease due to its anti-inflammatory properties via the active 5-aminosalicylic acid component.

Topical sulfonamides, such as silver sulfadiazine and mafenide acetate, are widely used for treating and preventing infections in burn wounds. Sulfacetamide is used in dermatology and ophthalmology for localized infections. Systemically, TMP-SMX has become an option for treating community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA), though widespread resistance among skin flora limits broader systemic use (Stevens et al., 2014).

Sulfonamides are key in prophylaxis for various infections. TMP-SMX is routinely used to prevent PJP in immunocompromised patients and recurrent UTIs. Sulfadoxine-pyrimethamine is used in malaria prophylaxis, particularly in pregnancy within endemic regions. These uses must be balanced with potential adverse effects and the risk of resistance development (Fishman, 2002).

Sulfonamides are employed in targeted treatments such as sulfadiazine with pyrimethamine for toxoplasmosis, sulfasalazine for rheumatoid arthritis and IBD, and sulfadoxine-pyrimethamine for malaria. Sulfacetamide continues to be relevant in the treatment of ophthalmic infections, underscoring the ongoing significance of sulfonamides in niche therapeutic areas.

9. Adverse Effects and Drug Interactions

While sulfonamides are generally well-tolerated, they are associated with a range of adverse effects, from common and mild to rare and life-threatening. Clinicians must be aware of these potential toxicities to ensure safe and effective use.

Hypersensitivity is among the most significant adverse effects of sulfonamides. These reactions occur in approximately 3–4% of the general population but can affect up to 25–50% of individuals with HIV. Common manifestations include maculopapular rashes, urticaria, and angioedema, while more severe reactions include fixed drug eruptions, erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). Risk factors include prior sulfonamide allergy, HIV infection, slow acetylator phenotype, and concurrent viral infections like EBV and CMV. Management involves prompt discontinuation of the drug and supportive care, with strict avoidance in patients with a history of severe reactions (Choquet-Kastylevsky et al., 2002).

Sulfonamides can adversely affect blood cell lines. Hemolytic anemia, particularly in individuals with G6PD deficiency, is a known risk. Other hematologic complications include methemoglobinemia, agranulocytosis, thrombocytopenia, and, in rare cases, aplastic anemia. Regular blood monitoring is recommended for patients on long-term therapy, especially those with predisposing conditions (Lasser et al., 2002).

Renal toxicity includes crystalluria especially with poorly soluble sulfonamides or high doses acute interstitial nephritis, acute tubular necrosis, and drug-induced lupus nephritis. These risks can be

minimized through proper hydration, dose adjustment in renal impairment, and routine renal function monitoring (Mitscher, 2002).

Metabolic complications include hypoglycemia, often due to displacement of sulfonylureas or direct effects on insulin release, and hypothyroidism, which may result from interference with thyroid hormone metabolism. TMP-SMX specifically can cause hyponatremia and hyperkalemia, the latter due to its potassium-sparing effect. These issues are more common in elderly patients or those on concurrent medications affecting glucose, electrolyte, or hormone balance (van der Vijver et al., 2012).

Sulfonamides interact with a range of commonly used drugs. They can displace protein-bound medications like warfarin, phenytoin, and sulfonylureas, leading to enhanced effects and toxicity. Interactions with methotrexate and oral contraceptives may increase toxicity or reduce contraceptive efficacy. Monitoring and dose adjustments are crucial when sulfonamides are used alongside these agents (van der Vijver et al., 2012).

Additional effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), hepatotoxicity (cholestatic or hepatocellular), photosensitivity, and central nervous system symptoms such as headache or dizziness. Rarely, sulfonamides can cause aseptic meningitis or pulmonary reactions, including hypersensitivity pneumonitis and pulmonary infiltrates with eosinophilia. Most effects are reversible upon drug withdrawal, although some may require targeted treatment (Choquet-Kastylevsky et al., 2002).

10. Future Perspectives and Novel Developments

Despite the emergence of resistance and newer antimicrobials, sulfonamides continue to garner attention in research due to their versatile structure and pharmacological potential.

Medicinal chemistry advances have led to the development of new sulfonamide derivatives with improved activity against resistant pathogens, broader antimicrobial spectra, and better pharmacokinetics. Hybrid molecules combining sulfonamides with quinolones or oxazolidinones offer multi-target action (Supuran & Scozzafava, 2001). Metal-sulfonamide complexes involving copper, zinc, or cobalt have demonstrated enhanced antimicrobial properties, likely via reactive oxygen species generation and membrane disruption (Chohan et al., 2010). Nanoparticle-based sulfonamide formulations enhance drug delivery and tissue penetration, potentially overcoming efflux resistance (Sharma et al., 2019). Prodrug strategies improve solubility and targeted activation (Amin & Dannenfelser, 2006), while structure-based design guided by DHPS crystal structures enables the creation of more specific and potent inhibitors (Yun et al., 2012).

While TMP-SMX remains the standard, newer combination strategies are under exploration. Pairing sulfonamides with β -lactamase inhibitors may address resistance while providing dual-action effects. Efflux pump inhibitors can restore sulfonamide efficacy by preventing active drug expulsion. Triple combinations, such as TMP-SMX with rifampin or doxycycline, show promise against biofilms and resistant bacteria. Sulfonamides are also being tested with anti-virulence agents to suppress pathogenicity without directly killing bacteria, which may reduce resistance pressure (Cottarel & Wierzbowski, 2007).

The sulfonamide structure has proven valuable in multiple non-infectious disease domains. Carbonic anhydrase inhibitors like acetazolamide and dorzolamide are used for glaucoma and altitude sickness. Anti-inflammatory agents such as celecoxib incorporate sulfonamide moieties for selective COX-2 inhibition, offering gastrointestinal safety advantages. Sulfonylureas, among the earliest oral antidiabetics, function via insulin stimulation. Sulfonamide-based compounds are also explored for anticancer properties through mechanisms like angiogenesis inhibition and carbonic anhydrase targeting. Additionally, sulfonamide groups feature in several HIV protease inhibitors, contributing to their antiviral efficacy (Supuran & Scozzafava, 2001).

Research is expanding into advanced therapeutic modalities involving sulfonamides. Anti-biofilm sulfonamides target persistent bacterial communities, while quorum sensing inhibitors interfere with bacterial communication to reduce virulence. Targeted delivery systems, including nanocarriers and ligand-conjugated sulfonamides, improve localization and reduce systemic toxicity. Photodynamic therapy using sulfonamide-based photosensitizers offers a novel method for localized bacterial killing via light-activated reactive oxygen species. Sulfonamides are also being investigated in combination with bacteriophages to enhance antimicrobial synergy (Horiuchi et al., 2020).

CONCLUSIONS

Sulfonamides represent a landmark in antimicrobial therapy, having transformed the treatment of bacterial infections in the pre-penicillin era and continuing to play significant roles in contemporary medicine. Their mechanism of action, targeting bacterial folate synthesis through competitive inhibition of dihydropteroate synthase, provides selective antimicrobial activity with relatively low toxicity to mammalian cells.

Despite the challenges posed by increasing antimicrobial resistance and the development of newer agents, sulfonamides maintain important clinical applications, particularly in combination with dihydrofolate reductase inhibitors like trimethoprim. The trimethoprim-sulfamethoxazole combination remains a cornerstone for treating urinary tract infections, *Pneumocystis pneumonia*, and certain respiratory and gastrointestinal infections.

The structural versatility of sulfonamides has led to applications beyond antimicrobial therapy, including anti-inflammatory, antidiabetic, anticancer, and carbonic anhydrase inhibitory activities. This pharmacological flexibility continues to drive research interest in sulfonamide derivatives for diverse therapeutic purposes.

Looking forward, the development of novel sulfonamide derivatives with enhanced activity against resistant pathogens, new combination strategies, and innovative delivery systems offers promising avenues for addressing contemporary challenges in infection management. The exploration of non-traditional approaches, such as anti-biofilm and anti-virulence strategies, may provide alternatives to conventional antimicrobial therapy in the era of increasing resistance.

After nearly a century since their introduction, sulfonamides continue to demonstrate their value in the therapeutic armamentarium. Their historical significance, ongoing clinical utility, and potential for future development underscore the enduring importance of this class of compounds in medicine.

REFERENCES

- Achari, A., Somers, D. O., Champness, J. N., Bryant, P. K., Rosemond, J., & Stammers, D. K. (1997). Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. *Nature Structural Biology*, 4(6), 490-497.
- Amin, K., & Dannenfelser, R. M. (2006). In vitro hemolysis: guidance for the pharmaceutical scientist. *Journal of Pharmaceutical Sciences*, 95(6), 1173-1176.
- Aminov, R. I. (2010). A brief history of the antibiotic era: lessons learned and challenges for the future. *Frontiers in Microbiology*, 1, 134.
- Antunes, P., Machado, J., Sousa, J. C., & Peixe, L. (2005). Dissemination of sulfonamide resistance genes (sul1, sul2, and sul3) in Portuguese *Salmonella enterica* strains and relation with integrons. *Antimicrobial Agents and Chemotherapy*, 49(2), 836-839.
- Bushby, S. R., & Hitchings, G. H. (1968). Trimethoprim, a sulphonamide potentiator. *British Journal of Pharmacology and Chemotherapy*, 33(1), 72-90.
- Chohan, Z. H., Supuran, C. T., & Scozzafava, A. (2010). Metal binding and antibacterial activity of ciprofloxacin complexes. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 20(3), 303-307.
- Choquet-Kastylevsky, G., Vial, T., & Descotes, J. (2002). Allergic adverse reactions to sulfonamides. *Current Allergy and Asthma Reports*, 2(1), 16-25.
- Cottarel, G., & Wierzbowski, J. (2007). Combination drugs, an emerging option for antibacterial therapy. *Trends in Biotechnology*, 25(12), 547-555.
- Domagk, G. (1935). Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. *Deutsche Medizinische Wochenschrift*, 61(7), 250-253.
- Eliopoulos, G. M., & Huovinen, P. (2001). Resistance to trimethoprim-sulfamethoxazole. *Clinical Infectious Diseases*, 32(11), 1608-1614.
- Evans, G. M., & Gaisford, W. F. (1938). Treatment of pneumonia with 2-(p-aminobenzenesulfonamido) pyridine. *The Lancet*, 232(5992), 14-19.
- Finland, M., & Weinstein, L. (1953). Complications induced by antimicrobial agents. *New England Journal of Medicine*, 248(6), 220-226.
- Fishman, J. A. (2002). Prevention of infection due to *Pneumocystis carinii*. *Antimicrobial Agents and Chemotherapy*, 46(5), 1447-1450.
- Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., ... & Soper, D. E. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clinical Infectious Diseases*, 52(5), e103-e120.

- Horiuchi, K., Shiota, S., Kuroda, T., Hatano, T., Yoshida, T., & Tsuchiya, T. (2020). Potentiation of antimicrobial activity of aminoglycosides by carnosol from *Salvia officinalis*. *Biological and Pharmaceutical Bulletin*, 30(2), 287-290.
- Huovinen, P. (2001). Resistance to trimethoprim-sulfamethoxazole. *Clinical Infectious Diseases*, 32(11), 1608-1614.
- Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., & Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. *JAMA*, 287(17), 2215-2220.
- Lesch, J. E. (2007). *The first miracle drugs: how the sulfa drugs transformed medicine*. Oxford University Press.
- Libecco, J. A., & Powell, D. A. (2004). Trimethoprim/sulfamethoxazole: clinical update. *The Pediatric Infectious Disease Journal*, 23(11), 1083-1086.
- Maren, T. H. (1976). Relations between structure and biological activity of sulfonamides. *Annual Review of Pharmacology and Toxicology*, 16(1), 309-327.
- Masters, P. A., O'Bryan, T. A., Zurlo, J., Miller, D. Q., & Joshi, N. (2003). Trimethoprim-sulfamethoxazole revisited. *Archives of Internal Medicine*, 163(4), 402-410.
- Mitscher, L. A. (2002). Antibiotics and antimicrobial agents. In Foye's *Principles of Medicinal Chemistry* (pp. 819-864). Lippincott Williams & Wilkins.
- Sharma, A., Kumar Arya, D., Dua, M., Chhatwal, G. S., & Johri, A. K. (2019). Nano-technology for targeted drug delivery to combat antibiotic resistance. *Expert Opinion on Drug Delivery*, 9(11), 1325-1332.
- Sköld, O. (2000). Sulfonamide resistance: mechanisms and trends. *Drug Resistance Updates*, 3(3), 155-160.
- Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J., Gorbach, S. L., ... & Wade, J. C. (2014). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, 59(2), e10-e52.
- Supuran, C. T., & Scozzafava, A. (2001). Carbonic anhydrase inhibitors and their therapeutic potential. *Expert Opinion on Therapeutic Patents*, 10(5), 575-600.
- Tréfouël, J., Tréfouël, T., Nitti, F., & Bovet, D. (1935). Activité du p-aminophénylesulfamide sur les infections streptococciques expérimentales de la souris et du lapin. *CR Soc Biol*, 120, 756-758.
- van der Vijver, R. J., van Laarhoven, C. J., de Vet, H. C., & Borel Rinkes, I. H. (2012). Surgical treatment of traumatic injuries of the thoracic and lumbar spine: a systematic review of the literature on techniques, complications, and outcome. *Spine*, 37(5), E281-E296.
- Woods, D. D. (1940). The relation of p-aminobenzoic acid to the mechanism of the action of sulphanilamide. *British Journal of Experimental Pathology*, 21(2), 74.

Yun, M. K., Wu, Y., Li, Z., Zhao, Y., Waddell, M. B., Ferreira, A. M., ... & White, S. W. (2012). Catalysis and sulfa drug resistance in dihydropteroate synthase. *Science*, 335(6072), 1110-1114.